Other News To Note
Wednesday, February 6, 2013
Isotechnika Pharma Inc., of Edmonton, Alberta, and privately held Aurinia Pharmaceuticals Inc., of Victoria, British Columbia, said they signed a binding term sheet for a merger to create a clinical-stage firm focused on the global nephrology market. Under the terms, Isotechnika will acquire 100 percent of the outstanding securities of Aurinia, a spinout of Swiss company Galenica Group's Vifor Pharma unit, and the deal will result in a 60-40 postmerger ownership, with Isotechnika retaining the larger portion.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.